CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; CIBB - Center for Innovation in Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal; IIIUC - Institute for Interdisciplinary Research, University of Coimbra, Coimbra, Portugal.
CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; CIBB - Center for Innovation in Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal; Institute of Physiology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Curr Opin Neurobiol. 2023 Apr;79:102694. doi: 10.1016/j.conb.2023.102694. Epub 2023 Feb 24.
Type 2 diabetes (T2D) and Alzheimer's disease (AD) are two global epidemics that share several metabolic defects, such as insulin resistance, impaired glucose metabolism, and mitochondrial defects. Importantly, strong evidence demonstrates that T2D significantly increases the risk of cognitive decline and dementia, particularly AD. Here, we provide an overview of the metabolic defects that characterize and link both pathologies putting the focus on mitochondria. The biomarker potential of mitochondrial components and the therapeutic potential of some drugs that target and modulate mitochondria are also briefly discussed.
2 型糖尿病（T2D）和阿尔茨海默病（AD）是两种全球性的流行病，它们具有一些共同的代谢缺陷，如胰岛素抵抗、葡萄糖代谢受损和线粒体缺陷。重要的是，有强有力的证据表明，T2D 显著增加了认知能力下降和痴呆症的风险，尤其是 AD。在这里，我们提供了一个概述，描述了两种病理特征和联系的代谢缺陷，并将重点放在了线粒体上。我们还简要讨论了线粒体成分的生物标志物潜力和一些靶向和调节线粒体的药物的治疗潜力。
